Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 600 people, planned
- Started
- 2 Nov 2004
- Expected to end
- 31 Dec 2030
- Type of study
- Observational
- Treatments tested
- Observational study
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Bilateral disease
- Presence of at least three peripapillary "birdshot lesions" inferior or nasal to the optic disk in one eye
- Low-grade anterior segment intraocular inflammation (defined as ≤ 1+cells in the anterior chamber)
- Low grade vitreous inflammatory reaction (defined as ≤ 2+ vitreous haze‡) Supportive findings
- HLA-A29 positivity 2. Retinal vasculitis 3. Cystoid macular edema
Who cannot take part
- Presence of infectious, neoplastic, or other inflammatory diseases that can cause multifocal choroidal lesions
- Keratic precipitates
- Posterior synechiae
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is twofold:
Read full original descriptionShow less
1. To analyze the clinical features of a cohort of patients with birdshot chorioretinopathy (BCR), an inflammatory bilateral ocular disease, affecting the choroid and the retina.
Various imaging techniques will be used to assess the effect of the disease on the retina and the choroid.
A standardized assessment of the visual function will be performed with visual acuity, visual field and color vision testing. The quality of life of the patients will be evaluated with the VFQ-25 questionnaire.
These analyses will help delineating different forms of the disease among its heterogeneous presentations. 2. To identify predisposing factors for the disease. The condition is unique from the immunogenetic standpoint by its association with the HLA-A29 allele, which is the strongest link between an HLA class I antigen and a disease. To date, however, the mechanisms leading to birdshot chorioretinopathy remain unknown. GWAS (Genome Wide association Study) based on DNA of the cohort patients will be performed with the aim to identify other susceptibility genes associated with BCR.
The group in the trial
- Birdshot chorioretinopathy
Patients with a diagnosis of birdshot chorioretinopathy, with confirmed HLA-A29 positivity.
Treatment: Observational study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Longitudinal Cohort Study of Patients With Birdshot Chorioretinopathy.
- Record updated
- 4 March 2026